Vanda Pharmaceuticals Reinstates Guidance; Sees FY24 Total Revenues $180M-$210M
Portfolio Pulse from Benzinga Newsdesk
Vanda Pharmaceuticals has reinstated its guidance for the fiscal year 2024, projecting total revenues between $180 million and $210 million.
July 31, 2024 | 8:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vanda Pharmaceuticals has reinstated its guidance for FY24, projecting total revenues between $180 million and $210 million. This reinstatement provides clarity and could boost investor confidence.
The reinstatement of guidance provides clarity on the company's financial outlook, which is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100